CytRx research finds suppression of RIP140 controls insulin

By Lisa Kerner

Erie, Pa., Feb. 2 - CytRx Corp. said its research indicates for the first time that RIP140 suppression by small interfering RNA (siRNA) in cell culture or by gene-deletion in mice enhances glucose tolerance and insulin responsiveness.

CytRx has exclusive rights to intellectual property covering a drug screening method targeting RIP140, a nuclear hormone corepressor that regulates fat accumulation, according to a company news release.

The research findings were published in an article, entitled "Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes," in the January 2006 issue of The Journal of Clinical Investigation.

"Our paper reports that depletion of RIP140 in vivo can improve responsiveness to insulin under circumstances such as a high-fat diet, where normal animals develop insulin resistance and type 2 diabetes. We are encouraged that our results indicate that RIP140 appears to be an ideal target for developing RNAi therapeutics to treat obesity and type 2 diabetes," Michael P. Czech, PhD, one of the principle authors of the article, said.

CytRx is a Los Angeles-based biopharmaceutical research and development company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.